Who are Fludarabine plus Cyclophosphamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludarabine and Melphalan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludarabine-plus-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fludarabine plus Cyclophosphamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludarabine plus Cyclophosphamide (Fludarabine plus Cyclophosphamide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (purine analog + alkylating agent). Area: Oncology.

phase 3 Chemotherapy combination (purine analog + alkylating agent) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fludarabine plus Cyclophosphamide (Fludarabine plus Cyclophosphamide) — German CLL Study Group. Fludarabine and cyclophosphamide work together as a chemotherapy combination that damages cancer cell DNA and suppresses immune function to treat chronic lymphocytic leukemia.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fludarabine plus Cyclophosphamide TARGET	Fludarabine plus Cyclophosphamide	German CLL Study Group	phase 3	Chemotherapy combination (purine analog + alkylating agent)
Fludarabine and Melphalan	Fludarabine and Melphalan	First Affiliated Hospital of Zhejiang University	phase 3	Cytotoxic chemotherapy combination (purine analog + alkylating agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (purine analog + alkylating agent) class)

German CLL Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludarabine plus Cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/fludarabine-plus-cyclophosphamide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing